Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription Articles published in Cancer Imaging Retrieve available abstracts of 43 articles: HTML format

Single Articles

July 2026
1. IBRAHIM EA, Alper E
   When PSMA is not enough: the diagnostic blind spots of PSMA PET/CT and the added value of [(1)(8)F]FDG in high-risk prostate cancer: dual-tracer cohort study.
   Cancer Imaging. 2026 Jul 2. doi: 10.1186/s40644-026-01084.
   PubMed     Abstract available
   
   
   June 2026
2. PADDEN-MODI M, Taprogge J, Dutey-Magni P, Cauduro CGS, et al
   Predictive imaging biomarkers on whole-body diffusion-weighted MRI (WB-DWMRI) and [(68)Ga]GaPSMA-PET/CT for [(177)Lu]LuPSMA therapy in metastatic prostate cancer (mCRPC).
   Cancer Imaging. 2026;26:84.
   PubMed     Abstract available
   
   
   
3. CHO S, Seo HJ, Han H, Lee S, et al
   The feasibility of [(18)F]PSMA-1007 PET/CT for response assessment in prostate cancer following neoadjuvant androgen deprivation therapy compared with mpMRI.
   Cancer Imaging. 2026 Jun 23. doi: 10.1186/s40644-026-01073.
   PubMed     Abstract available
   
   
   
4. CUI J, Liu Y, Wang G, Xu X, et al
   [(18)F] PSMA-3Q PET/CT radiomics at 45% SUVmax threshold: predicting post-surgical ISUP grade >/= 4 and extraprostatic extension for noninvasive stratification in prostate cancer management.
   Cancer Imaging. 2026 Jun 6. doi: 10.1186/s40644-026-01050.
   PubMed     Abstract available
   
   
   April 2026
5. ATASEVER T, Babacan GB, Ekinci OB, Buyukkuscu A, et al
   Prognostic value of PSMA PET-derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
   Cancer Imaging. 2026 Apr 30. doi: 10.1186/s40644-026-01036.
   PubMed     Abstract available
   
   
   
6. DO DD, Domingo MR, Conlin CC, Matthews I, et al
   Systematic effects of patient factors and scanner/protocol factors on a Restriction Spectrum Imaging (RSI) quantitative MRI biomarker for prostate cancer.
   Cancer Imaging. 2026 Apr 16. doi: 10.1186/s40644-026-01032.
   PubMed    
   
   
   February 2026
7. POROES F, Nobile A, Widmer L, Vidal J, et al
   Maximal radial distance for predicting extraprostatic extension of prostate cancer: a histopathological-radiological study.
   Cancer Imaging. 2026 Feb 21. doi: 10.1186/s40644-026-01011.
   PubMed    
   
   
   January 2026
8. LIN LP, Cheng XW, Chen J, Li SY, et al
   Prognostic features of biochemical recurrence of prostate cancer following radical prostatectomy based on diffusion kurtosis imaging.
   Cancer Imaging. 2026 Jan 28. doi: 10.1186/s40644-026-00997.
   PubMed    
   
   
   
9. LOWRY NC, Breto AL, Wallaengen V, Algohary A, et al
   MRI-based patient selection for active surveillance in prostate cancer using U-Found: a generalized deep learning model.
   Cancer Imaging. 2026 Jan 19. doi: 10.1186/s40644-026-00988.
   PubMed    
   
   
   December 2025
10. BERG EK, Kunte SC, Zahner J, Holzgreve A, et al
    PSMA expression assessed by [(18)F]PSMA-1007 PET/CT imaging in metastatic hormone-sensitive prostate cancer patients treated with apalutamide.
    Cancer Imaging. 2025;25:136.
    PubMed     Abstract available
    
    
    September 2025
11. MIN K, Lin Q, Qiu D
    Precision medicine in prostate cancer: individualized treatment through radiomics, genomics, and biomarkers.
    Cancer Imaging. 2025;25:116.
    PubMed     Abstract available
    
    
    August 2025
12. A GLEMSER P, Netzer N, H Ziener C, Wilhelm M, et al
    Improving risk stratification of PI-RADS 3 + 1 lesions of the peripheral zone: expert lexicon of terms, multi-reader performance and contribution of artificial intelligence.
    Cancer Imaging. 2025;25:102.
    PubMed     Abstract available
    
    
    
13. YAO F, Lin H, Xue YN, Zhuang YD, et al
    Multimodal imaging deep learning model for predicting extraprostatic extension in prostate cancer using MpMRI and 18 F-PSMA-PET/CT.
    Cancer Imaging. 2025;25:103.
    PubMed     Abstract available
    
    
    July 2025
14. CHEN R, Li Y, Liang D, Liu J, et al
    PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy.
    Cancer Imaging. 2025;25:93.
    PubMed     Abstract available
    
    
    
15. ZAMANIAN A, Rousseau E, Buteau FA, Arsenault F, et al
    The tumour sink effect on (68)Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study.
    Cancer Imaging. 2025;25:91.
    PubMed     Abstract available
    
    
    
16. KORN SM, Qian Z, Zurl H, Hansen N, et al
    Geographic variability in contemporary utilization of PET imaging for prostate cancer: a medicare claims cohort study.
    Cancer Imaging. 2025;25:86.
    PubMed     Abstract available
    
    
    
17. YANG L, Jin P, Wang X, Li Z, et al
    Development and validation of a novel clinical-radiological-pathological scoring system for preoperative prediction of extraprostatic extension in prostate cancer: a multicenter retrospective study.
    Cancer Imaging. 2025;25:83.
    PubMed     Abstract available
    
    
    June 2025
18. BIAN L, Liu F, Peng Y, Liu X, et al
    Using radiomics model for predicting extraprostatic extension with PSMA PET/CT studies: a comparative study with the Mehralivand grading system.
    Cancer Imaging. 2025;25:77.
    PubMed     Abstract available
    
    
    April 2025
19. MOAVENZADEH SR, Chan DY, Adams ES, Deivasigamani S, et al
    Evaluation of 3D ARFI imaging of prostate cancer: diagnostic reliability and concordance with MpMRI.
    Cancer Imaging. 2025;25:55.
    PubMed     Abstract available
    
    
    
20. ZEDAN AH, Gade JS, Zieger KEA, Poulsen MH, et al
    Cabazitaxel-induced ureteritis in metastatic castration-resistant prostate cancer patients: a single center case series 2014-2024.
    Cancer Imaging. 2025;25:54.
    PubMed     Abstract available
    
    
    March 2025
21. SUN Z, Wu P, Zhao T, Gao G, et al
    Deep learning-based fully automated detection and segmentation of pelvic lymph nodes on diffusion-weighted images for prostate cancer: a multicenter study.
    Cancer Imaging. 2025;25:37.
    PubMed     Abstract available
    
    
    
22. POROES F, Karampa P, Sartoretti T, Najberg H, et al
    Additional findings in prostate MRI.
    Cancer Imaging. 2025;25:29.
    PubMed     Abstract available
    
    
    January 2025
23. HUANG X, Ye H, Hu Y, Lei Y, et al
    Ultrasound super-resolution imaging for non-invasive assessment of microvessel in prostate lesion.
    Cancer Imaging. 2025;25:1.
    PubMed     Abstract available
    
    
    October 2024
24. BURGARD C, Rosar F, Larsen E, Khreish F, et al
    Outstanding increase in tumor-to-background ratio over time allows tumor localization by [(89)Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer.
    Cancer Imaging. 2024;24:132.
    PubMed     Abstract available
    
    
    September 2024
25. VENTURA D, Rassek P, Schindler P, Akkurt BH, et al
    Early treatment response assessment with [(177)Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET.
    Cancer Imaging. 2024;24:126.
    PubMed     Abstract available
    
    
    August 2024
26. HARSINI S, Martineau P, Plaha S, Saprunoff H, et al
    Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.
    Cancer Imaging. 2024;24:117.
    PubMed     Abstract available
    
    
    
27. XU L, Peng Q, Zhang G, Zhang D, et al
    Development of preoperative nomograms to predict the risk of overall and multifocal positive surgical margin after radical prostatectomy.
    Cancer Imaging. 2024;24:104.
    PubMed     Abstract available
    
    
    July 2024
28. FURMAN B, Falick Michaeli T, Den R, Ben Haim S, et al
    Pelvic lymph node mapping in prostate cancer: examining the impact of PSMA PET/CT on radiotherapy decision-making in patients with node-positive disease.
    Cancer Imaging. 2024;24:96.
    PubMed     Abstract available
    
    
    
29. KALLIS K, Conlin CC, Zhong AY, Hussain TS, et al
    Comparison of synthesized and acquired high b-value diffusion-weighted MRI for detection of prostate cancer.
    Cancer Imaging. 2024;24:89.
    PubMed     Abstract available
    
    
    
30. YANG J, Xiao L, Zhou M, Li Y, et al
    [(68)Ga]Ga?PSMA?617 PET-based radiomics model to identify candidates for active surveillance amongst patients with GGG 1-2 prostate cancer at biopsy.
    Cancer Imaging. 2024;24:86.
    PubMed     Abstract available
    
    
    
31. GROSS M, Eisenhuber E, Assinger P, Schima R, et al
    MRI-guided in-bore biopsy of the prostate - defining the optimal number of cores needed.
    Cancer Imaging. 2024;24:81.
    PubMed     Abstract available
    
    
    May 2024
32. AYATI N, McIntosh L, Buteau J, Alipour R, et al
    Comparison of quantitative whole body PET parameters on [(68)Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prosta
    Cancer Imaging. 2024;24:57.
    PubMed     Abstract available
    
    
    April 2024
33. KOLADE OU, Brink A, Ayeni AO, More S, et al
    Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study.
    Cancer Imaging. 2024;24:46.
    PubMed     Abstract available
    
    
    February 2024
34. YAZDANI E, Karamzadeh-Ziarati N, Cheshmi SS, Sadeghi M, et al
    Automated segmentation of lesions and organs at risk on [(68)Ga]Ga-PSMA-11 PET/CT images using self-supervised learning with Swin UNETR.
    Cancer Imaging. 2024;24:30.
    PubMed     Abstract available
    
    
    
35. ROSAR F, Burgard C, Larsen E, Khreish F, et al
    [(89)Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [(68)Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis.
    Cancer Imaging. 2024;24:27.
    PubMed     Abstract available
    
    
    
36. GUERRA A, Orton MR, Wang H, Konidari M, et al
    Clinical application of machine learning models in patients with prostate cancer before prostatectomy.
    Cancer Imaging. 2024;24:24.
    PubMed     Abstract available
    
    
    
37. HU C, Qiao X, Hu C, Cao C, et al
    The practical clinical role of machine learning models with different algorithms in predicting prostate cancer local recurrence after radical prostatectomy.
    Cancer Imaging. 2024;24:23.
    PubMed     Abstract available
    
    
    January 2024
38. MA Y, Gao F
    Advances of radiolabeled GRPR ligands for PET/CT imaging of cancers.
    Cancer Imaging. 2024;24:19.
    PubMed     Abstract available
    
    
    December 2023
39. DONNERS R, Figueiredo I, Westaby D, Koh DM, et al
    Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer.
    Cancer Imaging. 2023;23:121.
    PubMed     Abstract available
    
    
    November 2023
40. PENG Q, Xu L, Zhang G, Zhang D, et al
    Effect of preoperative PI-RADS assessment on pathological outcomes in patients who underwent radical prostatectomy.
    Cancer Imaging. 2023;23:113.
    PubMed     Abstract available
    
    
    
41. LUO L, Zheng A, Chang R, Li Y, et al
    Evaluating the value of (18)F-PSMA-1007 PET/CT in the detection and identification of prostate cancer using histopathology as the standard.
    Cancer Imaging. 2023;23:108.
    PubMed     Abstract available
    
    
    September 2023
42. HU B, Zhang H, Zhang Y, Jin Y, et al
    A nomogram based on biparametric magnetic resonance imaging for detection of clinically significant prostate cancer in biopsy-naive patients.
    Cancer Imaging. 2023;23:82.
    PubMed     Abstract available
    
    
    
43. YANG J, Li J, Xiao L, Zhou M, et al
    (68)Ga-PSMA PET/CT-based multivariate model for highly accurate and noninvasive diagnosis of clinically significant prostate cancer in the PSA gray zone.
    Cancer Imaging. 2023;23:81.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum